Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05275673
Recruitment Status : Recruiting
First Posted : March 11, 2022
Last Update Posted : August 8, 2022
Sponsor:
Information provided by (Responsible Party):
Calithera Biosciences, Inc

Brief Summary:
This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC should have disease that has progressed on or after at least two prior systemic therapies for metastatic disease including platinum-doublet chemotherapy and a programmed cell death 1 ligand 1 (PD-L1) inhibitor. The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory sqNSCLC as two separate groups: Group A: NFE2L2-mutated sqNSCLC and Group B: NFE2L2-WT sqNSCLC.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Squamous Non-small-cell Lung Cancer Squamous Non-Small Cell Neoplasm of Lung NFE2L2 Gene Mutation Drug: sapanisertib Phase 2

Detailed Description:
NFE2L2 mutation status for all patients will be identified using local or central next generation sequencing (NGS) testing on archival or fresh tissue or circulating tumor deoxyribonucleic acid (ctDNA), the results of which must be reviewed and approved by the Sponsor prior to enrollment. Each group will be randomized 1:1 to one of two doses/schedules of sapanisertib. Approximately 30 NFE2L2-mutant and 20 NFE2L2-wild type patients will be enrolled. Patients will be treated with sapanisertib until disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, withdrawal of consent, or death.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

2 dosing schedules: 3 mg once per day (3 mg total) OR 2 mg twice per day (4 mg total)

Group A: 30 participants randomized 1:1 to one of two dosing schedules

Group B: approximately 20 participants randomized 1:1 to one of two dosing schedules

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Actual Study Start Date : April 15, 2022
Estimated Primary Completion Date : September 30, 2023
Estimated Study Completion Date : March 31, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Group A - NFE2L2 Mutation, Dosing Cohort 1
sapanisertib 3 mg once daily (QD)
Drug: sapanisertib
capsules for oral administration
Other Name: CB-228

Experimental: Group A - NFE2L2 Mutation, Dosing Cohort 2
sapanisertib 2 mg twice daily (BID)
Drug: sapanisertib
capsules for oral administration
Other Name: CB-228

Experimental: Group B - NFE2L2 Wild-Type, Dosing Cohort 1
sapanisertib 3 mg QD
Drug: sapanisertib
capsules for oral administration
Other Name: CB-228

Experimental: Group B - NFE2L2 Wild-Type, Dosing Cohort 2
sapanisertib 2 mg BID
Drug: sapanisertib
capsules for oral administration
Other Name: CB-228




Primary Outcome Measures :
  1. Investigator-Assessed Overall Response Rate (ORR) per RECIST v1.1. [ Time Frame: 36 months ]
    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) according to the RECIST v1.1 criteria as assessed by the investigator.

  2. Number of Participants With Adverse Events (AEs), Serious AEs, Deaths, and Discontinuations Due to AEs [ Time Frame: after the first dose of study drug through 28 days after the last dose of sapanisertib (up to 36 months) ]
    An adverse event (AE) is any untoward, undesired, or unplanned medical occurrence in a patient administered a medicinal product whether or not considered drug related. A serious adverse event (SAE) is an AE that occurs after receiving study treatment (or after signing informed consent and before receiving study treatment if due to a protocol-mandated procedure) that either results in death, is life-threatening, requires inpatient hospitalization, results in persistent or significant disability, results in congenital anomaly or birth defect, or otherwise meets criteria as an important medical event.


Secondary Outcome Measures :
  1. Duration of Response (DOR) [ Time Frame: 36 months ]
    DOR will be calculated as the time between the first documentation of partial response (PR) or a complete response (CR) to the first documentation of progressive disease or death, whichever occurs first.

  2. Progression-Free Survival (PFS) [ Time Frame: 36 months ]
    PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurs first.

  3. Overall Survival (OS) [ Time Frame: 36 months ]
    OS is defined as the time from randomization to death due to any cause.

  4. Overall Survival (OS) at 6 Months [ Time Frame: 6 months ]
    OS is defined as the time from randomization to death due to any cause.

  5. Overall Survival (OS) at 12 Months [ Time Frame: 12 months ]
    OS is defined as the time from randomization to death due to any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stage IV squamous NSCLC.
  • Disease progression during or after prior systemic therapy for metastatic disease, which must include platinum-doublet chemotherapy and immune checkpoint inhibitor therapy (anti-PD-(L)1 +/-anti-CTLA-4), if approved and available, administered as separate lines of therapy or in combination.
  • Has study-eligible mutation in NFE2L2 or wild-type NFE2L2 using NGS from a College of American Pathologists- (CAP)-accredited and/or a Clinical Laboratory Improvement Amendments- (CLIA)-certified laboratory
  • Must have at least one radiographically measurable lesion per RECIST v1.1 defined as a lesion that is ≥ 10 mm in longest diameter or lymph node that is ≥ 15 mm in short axis imaged by computerized tomography (CT) scan or Magnetic Resonance Imaging (MRI).
  • Target lesions situated in a previously irradiated area may be considered measurable if progression has been demonstrated subsequent to radiation therapy.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
  • Adequate Organ Function Laboratory Findings: Absolute neutrophil count (ANC): ≥1,500/mm3, Hemoglobin: ≥9.0 g/dL * Transfusions and growth factors must not be used within 2 weeks prior to randomization to meet these requirements, Platelets: ≥ 100,000/mm3, Calculated creatinine clearance (CrCl): ≥ 40mL/min, Serum total bilirubin: ≤ 1.5× upper limit of normal (ULN) OR ≤ 3 mg/dL for patients with Gilbert's disease, AST (SGOT) and ALT (SGPT): ≤ 2.5× ULN OR ≤ 5× ULN for patients with liver metastases, Fasting triglycerides: < 300 mg/dL, Fasting serum glucose: <160 mg/dL
  • A female patient of childbearing potential must:

    1. Have a negative serum or urine pregnancy test within 7 days prior to the first dose of study treatment
    2. Agree to use acceptable methods of contraception(See Section 8.1.2) during the study and for a minimum of 14 days following the last dose of sapanisertib
    3. Post-menopausal females (no menses for >1 year without an alternative medical cause) and surgically sterilized females are exempt from these requirements.
  • Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential and refrain from donating sperm during the study and for a minimum of 14 days following the last dose of sapanisertib.

Exclusion Criteria:

  • Non-squamous cell histology and mixed histology tumors with any small-cell/neuroendocrine component.
  • Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment per investigator's discretion.
  • Receipt before the first dose of study drug of any of the following:

    i. Any investigational agent within 4 weeks. ii. Chemotherapy with 3 weeks (6 weeks for nitrosoureas or mitomycin C) iii. Any radiotherapy within 2 weeks prior to randomization with the exception of palliative radiotherapy for isolated tumor lesions

  • Major surgery or other anticancer therapy not previously specified within 4 weeks.
  • Unable or unwilling to discontinue proton pump inhibitor (PPI) use ≥ 5 days prior to randomization.
  • Interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoid treatment.
  • Any condition including social, psychiatric or medical (including uncontrolled significant concurrent illness) that in the opinion of the Investigator could interfere with treatment or protocol-related procedures.
  • Patients who are pregnant or lactating.
  • Symptomatic ascites or pleural effusion. Exception: Patients who are clinically stable following treatment for these conditions (including therapeutic thoraco-or paracentesis) are eligible.
  • Refractory nausea and vomiting, uncontrolled diarrhea, malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes or other situation that may preclude adequate absorption of oral study medication.
  • Infection requiring more than 5 days of parenteral antibiotics, antivirals, or antifungals within two weeks prior to randomization.
  • Patients receiving systemic corticosteroids greater than prednisone 10 mg or equivalent (excluding inhalers or low-dose hormone replacement therapy) within the 7 days before treatment initiation.
  • Previous intolerance to mammalian target of rapamycin (mTOR), AKT, or dual PI3K/mTOR inhibitors.
  • Patients with symptomatic, active/untreated central nervous system metastasis and/or leptomeningeal disease are not eligible.
  • Significant active cardiovascular disease
  • Participants who are known to be HIV-positive, unless assessed to be healthy with a low risk of AIDS-related outcomes.
  • Known active Hepatitis B or C infection.
  • Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of the study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05275673


Contacts
Layout table for location contacts
Contact: Clinical Administrator 650-870-1000 clinicaltrials@calithera.com

Locations
Layout table for location information
United States, California
UC Davis Comprehensive Cancer Center Recruiting
Davis, California, United States, 95817
Contact: Nicole Terry    916-734-4913    nicterry@ucdavis.edu   
Providence Medical Group Santa Rosa - Cancer Center Recruiting
Santa Rosa, California, United States, 95403
Contact: Teresa Lund    707-521-3803    teresa.lund@stjoe.org   
Contact: Tracy Foster       tracy.foster@stjoe.org   
Principal Investigator: Ian C Anderson, MD         
United States, Kentucky
Norton Cancer Institute, Downtown Recruiting
Louisville, Kentucky, United States, 40202
Contact: John Hamm, MD    502-629-2500    Lung-NCIResearch@nortonhealthcare.org   
Principal Investigator: John Hamm, MD         
United States, Michigan
Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Hirva Mamdani, MD    313-576-8711    mamdanih@karmanos.org   
Principal Investigator: Hirva Mamdani, MD         
United States, Ohio
Zangmeister Cancer Center Recruiting
Columbus, Ohio, United States, 43219
Contact: Nancy Zangmeister    614-383-6236    Nancy.Zangmeister@aoncology.com   
Principal Investigator: Jorge Rios, MD         
United States, Oregon
Providence Cancer Institute Franz Clinic Not yet recruiting
Portland, Oregon, United States, 97213
Contact: Julie Cramer, MA    412-952-5634    Julie.Cramer@providence.org   
Principal Investigator: Rachel Sanborn, MD         
United States, Tennessee
Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
Contact: Kelly Goddard, RN       DDUreferrals@sarahcannon.com   
Principal Investigator: Melissa Johnson, MD         
Sponsors and Collaborators
Calithera Biosciences, Inc
Investigators
Layout table for investigator information
Study Director: Bradley J Sumrow, MD Calithera Biosciences, Inc
Layout table for additonal information
Responsible Party: Calithera Biosciences, Inc
ClinicalTrials.gov Identifier: NCT05275673    
Other Study ID Numbers: CX-228-301
First Posted: March 11, 2022    Key Record Dates
Last Update Posted: August 8, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: We do not plan to share the individual participant data with other researchers

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Calithera Biosciences, Inc:
NSCLC
sqNSCLC
NFE2L2
Next Generation Sequencing
NGS
Mutation
Relapsed
Refractory
Squamous
NRF2
Lung Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms